News Focus
News Focus
Followers 133
Posts 3773
Boards Moderated 0
Alias Born 01/28/2006

Re: bramkers post# 73146

Friday, 10/10/2014 12:38:04 AM

Friday, October 10, 2014 12:38:04 AM

Post# of 405212
I prefer a licensing agreement with a big pharma company and I think that is the most likely outcome. One of the difficulties with a buy out is how to value all the drugs in the pipeline that need to be studied. IMO many of the analogues of Brilacidin and Kevetrin will become successful pharmaceuticals in the future.

Several biotechs have been exploded by using a licensing strategy. See my previous posts regarding Regeneron #72594 and Brilacidin # 65557

Good luck, Farrell
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y